329 related articles for article (PubMed ID: 10810934)
1. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
Burris HA
Semin Oncol; 2000 Apr; 27(2 Suppl 3):19-23. PubMed ID: 10810934
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer.
Bullock K; Blackwell K
Oncologist; 2008 May; 13(5):515-25. PubMed ID: 18515736
[TBL] [Abstract][Full Text] [Related]
3. Recent progress in the clinical development of docetaxel (Taxotere).
Hortobagyi GN
Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
van Oosterom AT
Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel (Taxotere) in combination: a step forward.
Burris HA; Fields S; Peacock N
Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab in combination with chemotherapy for the treatment of metastatic breast cancer.
Fornier M; Esteva FJ; Seidman AD
Semin Oncol; 2000 Dec; 27(6 Suppl 11):38-45; discussion 92-100. PubMed ID: 11236027
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer.
Nabholtz JM; North S; Smylie M; Mackey J; Au HJ; Au R; Morrish D; Salter E; Tonkin K
Semin Oncol; 2000 Apr; 27(2 Suppl 3):11-8. PubMed ID: 10810933
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
Nabholtz JM
Semin Oncol; 1999 Jun; 26(3 Suppl 9):7-13. PubMed ID: 10426453
[TBL] [Abstract][Full Text] [Related]
9. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.
Coudert BP; Largillier R; Arnould L; Chollet P; Campone M; Coeffic D; Priou F; Gligorov J; Martin X; Trillet-Lenoir V; Weber B; Bleuse JP; Vasseur B; Serin D; Namer M
J Clin Oncol; 2007 Jul; 25(19):2678-84. PubMed ID: 17515572
[TBL] [Abstract][Full Text] [Related]
10. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
Crown J
Semin Oncol; 1999 Feb; 26(1 Suppl 3):5-9. PubMed ID: 10203264
[TBL] [Abstract][Full Text] [Related]
11. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).
Guarneri V; Frassoldati A; Bruzzi P; D'Amico R; Belfiglio M; Molino A; Bertetto O; Cascinu S; Cognetti F; Di Leo A; Pronzato P; Crinó L; Agostara B; Conte P
Clin Breast Cancer; 2008 Oct; 8(5):453-6. PubMed ID: 18952561
[TBL] [Abstract][Full Text] [Related]
12. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
Sparano JA
Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
[TBL] [Abstract][Full Text] [Related]
13. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Slamon D; Pegram M
Semin Oncol; 2001 Feb; 28(1 Suppl 3):13-9. PubMed ID: 11301370
[TBL] [Abstract][Full Text] [Related]
14. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
Nabholtz JM; Crown J
Semin Oncol; 1998 Dec; 25(6 Suppl 13):4-9. PubMed ID: 9865685
[TBL] [Abstract][Full Text] [Related]
15. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M
Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M
Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel in combination chemotherapy for metastatic breast cancer.
Khayat D; Antoine E
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer.
Burris HA
Semin Oncol; 2001 Feb; 28(1 Suppl 3):38-44. PubMed ID: 11301373
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial.
Hamberg P; Bos MM; Braun HJ; Stouthard JM; van Deijk GA; Erdkamp FL; van der Stelt-Frissen IN; Bontenbal M; Creemers GJ; Portielje JE; Pruijt JF; Loosveld OJ; Smit WM; Muller EW; Schmitz PI; Seynaeve C; Klijn JG;
Clin Breast Cancer; 2011 Apr; 11(2):103-13. PubMed ID: 21569996
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
Marty M; Cognetti F; Maraninchi D; Snyder R; Mauriac L; Tubiana-Hulin M; Chan S; Grimes D; Antón A; Lluch A; Kennedy J; O'Byrne K; Conte P; Green M; Ward C; Mayne K; Extra JM
J Clin Oncol; 2005 Jul; 23(19):4265-74. PubMed ID: 15911866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]